The 26th Annual Procrastinators Marathon: Hot Topic Updates

Share This Event

*Registration payment includes Credit Cards and Interfund Transfers ONLY.

Target Audience

Pharmacists

Description

This knowledge-based CPE activity will provide the healthcare professional with current and emerging evidence-based updates to help ensure best practices, minimize preventable healthcare related cost, and provide optimal patient care. Focused topic discussions will include updates in a wide area of topics including COPD, Heart Failure, Chronic Kidney Disease with Diabetes; CBD/THC, Geriatrics, Substance Use Disorder

Event Faculty:

Dejan (Dan) Landup, PharmD, HF-Cert

Tom Martin, PharmD, BCPS, CDE

Kristen Nagy PharmD, BCPS, BCPP

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP

Dennis Williams, PharmD, BCPS, AE-C

Tasha Woodall, PharmD, BCGP, CPP

Live Webinar Information
This webinar will be broadcast with Zoom. Instructions to join the webinar will be emailed prior to the event. Please go to our live webinar requirements page for more information and to test the computer/device and network prior to the event.

Continuing Education Credit For Pharmacists:
The University Of North Carolina Eshelman School Of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The program ACPE# 0046-9999-23-188-L01-P(Pharmacist) provides 6.0 contact hours of continuing pharmacy education credit. To receive CE credit, you must complete the CE attendance form and the evaluation of the program. Statement of credit can be viewed and printed in CPE Monitor. Statements of CE Credit will be processed in approximately 2 to 3 weeks. **No partial credit will be available**


Contact sarah.ashcraft@atriumhealth.org with questions.

Objectives

• Describe the factors and social determinants of health associated with determining the severity of COPD (Williams)
• Identify a stepwise approach to recommending pharmacotherapy for a patient with COPD (Williams)
• Review evidence and current recommendations for the use of kidney protective agents in persons with diabetes and chronic kidney disease (CKD).(Schumacher)
• State the proposed rationale for the nephroprotective effects of SGLT2 inhibitors. (Schumacher)
• Select an individualized therapy plan, including lifestyle modifications and pharmacotherapy, for a person with diabetes and CKD.(Schumacher)
• Identify an appropriate monitoring plan to evaluate the efficacy and safety of pharmacotherapy in the progression of CKD.(Schumacher)
• Describe key recommendations and recent updates in national guidelines regarding the care of persons with heart failure (Landup).
• Select an individualized therapy plan, including lifestyle modifications and pharmacotherapy for a person with heart failure.(Landup)
• Identify appropriate initiation and monitoring with SGLT-2 inhibitors in persons with HFrEF. (Landup)
• Discuss social determinants of health and their impact on the management of heart failure. (Landup)
• Recall how the endocannabinoid system interacts with other human body systems.(Nagy)
• Differentiate between CBD, Delta-8, Delta-9 and THC-O (Nagy)
• Describe racial disparities existing in cannabis use with legalization.(Nagy)
• Explain the concept of lag time to benefit and its utility in determining the appropriateness of bisphosphonate therapy and intensive blood pressure lowering in older adults. (Woodall)
• Define the role of lecanemab and other anti-amyloid therapies in treatment of dementia. (Woodall)
• Identify first- and second-line medications recommended for pharmacologic treatment of restless legs syndrome (per the updated RLS Foundation guidelines). (Woodall)
• Describe the impact of ageism and its intersection with other forms of bias on health outcomes. (Woodall)
• Discuss elements of Drug Addiction and Treatment Act of 2000 (DATA 2000) and its status as of June 2023 (Martin)
• State properties of buprenorphine that make it a reasonable choice for treating opioid use disorder (OUD) (Martin)
• Discuss current state of substance use disorder (SUD) and site specific risk factors and areas of greatest need and • state current trend in overdose rates among historically marginalized populations (HMP and discuss importance of internal bias and how it impacts access to care for SUD (Martin)
• Access tools and resources to assist with SUD treatment (Martin)

Sessions